Febuxostat in the management of hyperuricemia and chronic gout: a review
Miao Hu, Brian TomlinsonDivision of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, ChinaAbstract: Febuxostat is a novel, potent, non-purine selective xanthine oxidase inhibitor, wh...
Saved in:
Main Authors: | Miao Hu (Author), Brian Tomlinson (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2008-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
by: Tetsu Akimoto, et al.
Published: (2014) -
Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
by: Tetsu Akimoto, et al.
Published: (2014) -
Optimizing pulsatile release of febuxostat for managing gout flares: a chronotherapeutic approach
by: Khyati Parekh, et al.
Published: (2023) -
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
by: Sofue T, et al.
Published: (2014) -
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
by: Xudong Guan, et al.
Published: (2022)